Breaking News

Tweet TWEET

Aceto Announces Rising Pharmaceuticals Subsidiary Launches Generic Version of Soma(R) Compound With Aspirin and Codeine Tablets

Aceto Announces Rising Pharmaceuticals Subsidiary Launches Generic Version of
Soma(R) Compound With Aspirin and Codeine Tablets and Generic Version of
Decadron(R) Elixir

PORT WASHINGTON, N.Y., April 11, 2012 (GLOBE NEWSWIRE) -- Aceto Corporation
(Nasdaq:ACET), a global leader in the marketing, sales and distribution of
pharmaceutical intermediates and active ingredients, finished dosage form
generics, nutraceutical products, agricultural protection products and
specialty chemicals, today announced that Rising Pharmaceuticals Inc., its
finished dosage form generic subsidiary, has launched the 200mg/325 mg/16 mg
strengths of Carisoprodol, Aspirin and Codeine phosphate Tablets USP, an
approved generic version of Meda Pharmaceutical's Soma® Compound with Aspirin
and Codeine Tablets, and 0.5mg/5ml strength of Dexamethasone Elixir USP, an
approved generic version ofMerck & Co., Inc's., Decadron® Elixir, following
the U.S. Food and Drug Administration (FDA) approval of both Abbreviated New
Drug Applications (ANDA).According to IMS Health data, U.S. brand sales for
Carisoprodol, Aspirin and Codeine tablets, which is used to relieve pain and
muscle spasms, and Dexamethasone Elixir, which is a steroid used to treat
severe allergies, arthritis and asthma, were approximately $5.8 Million
collectively for the twelve months ended December, 2011.

ABOUT ACETO

Aceto Corporation, incorporated in 1947, is a global leader in the marketing
and distribution of pharmaceutical intermediates and active ingredients,
finished dosage form generics, nutraceutical products, agricultural protection
products and specialty chemicals.With business operations in nine countries,
Aceto distributes over 1,100 chemical compounds used principally as finished
products or raw materials in the pharmaceutical, nutraceutical, agricultural,
coatings and industrial chemical consuming industries.Aceto's global
operations, including a staff of 26 in China and 12 in India are distinctive
in the industry and enable its worldwide sourcing and regulatory capabilities.
(ACET-F)

This news release contains forward-looking statements as that term is defined
in the federal securities laws. To the extent any statements made in this news
release contain information that is not historical, these statements are
essentially forward-looking and as such, are subject to known and unknown
risks, uncertainties and contingencies, many of which are beyond the control
of the Company, which could cause actual results and outcomes to differ
materially from those expressed herein.Factors that could cause actual
results to differ materially from those set forth or implied by any
forward-looking statement include, but are not limited to, risks and
uncertainties discussed in Aceto's reports filed with the Securities and
Exchange Commission, including, but not limited to, Aceto's Annual Report or
Form 10-K for the fiscal year ended June 30, 2010 and other filings. Copies of
these filings are available at www.sec.gov.Aceto undertakes no obligation
to publicly update or revise any forward-looking statements, whether from new
information, future events or otherwise.

CONTACT: For information contact:
         Theodore Ayvas
         Director of Corporate Communications
         & Investor Relations
         Aceto Corporation
         (516) 627-6000
         www.aceto.com